Actiste® receives positive ratings in user-experience research
Brighter AB (publ) (Bolaget) today announces positive results for Actiste® in user-experience research. In the 90-day user-experience research conducted at two health centers in Sweden, patients with insulin-treated type-2 diabetes and the healthcare workers treating them gave Actiste Diabetes Management as a Service (ADMS) positive ratings. Brighter has published the results of Actiste[® ]user-experience research conducted at two healthcare centers in Sweden. The insights were presented at the Diabetes Forum 2021 conference in Gothenburg on December 1-3. To read more about the results,